Increase or decrease in folic acid content of the diet. Prevention of megaloblastic anemia and risk of neural tube defects in the newborn. (Source: Office of Dietary Supplments National Institutes of Health. Dietary Supplement Fact Sheet: Folate)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)

Periconceptional dolutegravir exposure was not associated with an increased risk of neural tube defects in live-born infants in either the MarketScan or Medicaid US databases, with zero NTD cases amon

Effect: null; NTD rate 6.8 per 10000 live births in dolutegravir group (Medicaid)